While the more linear impact on growth from increasing Cobimetinib doses on the BRAF mutant tumor subjected to a constant Belvarafenib dose (Figure 7b top, Figure S5) indicates that the drugs are acting in a more additive fashion. The gene discussed is BRAF; the disease is neoplasm.